Nutriventia Secures Growth Investment From NDude Labs to Expand Clinical Pipeline and US Operations

Nutriventia Private Limited, an India-based nutraceutical ingredients company, has closed a strategic growth investment from NDude Labs, an investment holding company focused on healthcare and wellness businesses.¹

Neither company disclosed the size of the investment.

The capital is intended to expand Nutriventia's clinical research pipeline, scale its proprietary E.D.G.E. low-dose delivery platform, and build a senior commercial team in the United States ahead of further expansion into Europe and the Asia-Pacific region.

For finished product manufacturers sourcing branded ingredients, the deal signals continued investor appetite for suppliers that anchor their ingredient portfolios in published clinical data rather than marketing claims alone.

"We built our proprietary delivery platforms to solve genuine pharmaceutical-grade challenges around bioavailability, stability, and dosing efficacy," said Vishal Shah, co-founder and managing director of Nutriventia, in the companies' announcement. "This partnership ensures that we can aggressively deepen our clinical pipeline and advance our delivery platforms without compromising on our scientific rigor."

What Will the Investment Fund at Nutriventia?

According to the announcement, the capital will support Nutriventia's existing branded ingredient portfolio, which includes TurmXTRA, CaffXtend, C-Fence, Melotime, Ashwanova, and ALAXTRA, alongside continued development of the company's E.D.G.E. delivery platform, which is designed to enable smaller, more targeted ingredient doses.¹

Nutriventia describes itself as backed by more than 40 years of pharmaceutical-grade formulation expertise and cites a portfolio of more than 50 studies, including 23 clinical trials and 19 peer-reviewed publications, along with 13 granted patents across a reported presence in 28 countries.

What Published Evidence Exists Behind Nutriventia's Ingredient Claims?

At least 1 ingredient in the portfolio, TurmXTRA, has clinical data published in an independent, peer-reviewed journal. A multicenter, randomized, double-blind, placebo-controlled trial in 106 adults with chronic knee pain found that 250 mg of the water-dispersible turmeric extract, delivering 150 mg of curcuminoids daily for 90 days, produced significantly greater pain reduction than placebo, with roughly 55% of treated participants achieving a clinically meaningful improvement compared with 14% on placebo, and no serious adverse events reported.²

That trial addresses a widely documented industry problem: curcumin, turmeric's primary active compound, is poorly absorbed and rapidly metabolized in its native form, the specific formulation challenge low-dose delivery platforms are designed to address.

Why Are Investors Targeting Bioavailability-Focused Ingredient Suppliers Now?

Nutriventia's leadership pointed to that clinical track record as the basis for the deal itself.

"Every stage of Nutriventia's growth has been anchored in one principle: lead with the science, and the market follows. NDude Labs recognized that our intellectual property is built on hard evidence rather than marketing narratives," said Rajat Mittal Shah, the company’s co-founder and executive director.

Nitin Thakor, managing director of NDude Labs, framed the investment similarly: "Nutriventia represents the kind of business we want to partner with at NDude Labs, science-led, innovation-driven and built in India with the potential to become a global category leader."¹ That framing reflects a broader pattern among ingredient buyers and investors placing more weight on independently published research as a differentiator in a crowded branded-ingredient market.

References

1. Nutriventia secures strategic growth investment from NDude Labs to accelerate global expansion. PrNutriventia Private Limited. Published September 17, 2026. Accessed September 18, 2026. Press release provided via email.

2. Thanawala S, Shah R, Somepalli V, Alluri KV, Desomayanandam P, Bhuvanendran A. A multicenter, randomized, double-blind, placebo-controlled trial assessing efficacy and safety of a novel low-dose turmeric extract formulation in healthy adults with chronic knee pain. Clin Pharmacol. 2021;13:91-100. doi:10.2147/CPAA.S307464